Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajeeva Singh

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Cancer Research|March 4, 2010
Antibody-maytansinoid conjugates designed to bypass multidrug resistanceYelena V Kovtun, Charlene A Audette, Michele F Mayo, et al.
Bioconjugate Chemistry|September 11, 2015
Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander KillingWayne C Widdison, Jose F Ponte, Jennifer A Coccia, et al.
Molecular Cancer Therapeutics|February 15, 2018
A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs)Michael L Miller, Manami Shizuka, Alan Wilhelm, et al.
Molecular Cancer Therapeutics|May 20, 2016
A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer CellsRajeeva Singh, Yulius Y Setiady, Jose Ponte, et al.
Frontiers in Immunology|March 8, 2024
IL11-mediated stromal cell activation may not be the master regulator of pro-fibrotic signaling downstream of TGFβYunhao Tan, Kenta Mosallanejad, Qingxiu Zhang, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Cancer Research|March 4, 2010
Antibody-maytansinoid conjugates designed to bypass multidrug resistanceYelena V Kovtun, Charlene A Audette, Michele F Mayo, et al.
Bioconjugate Chemistry|September 11, 2015
Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander KillingWayne C Widdison, Jose F Ponte, Jennifer A Coccia, et al.
Molecular Cancer Therapeutics|February 15, 2018
A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs)Michael L Miller, Manami Shizuka, Alan Wilhelm, et al.
Molecular Cancer Therapeutics|May 20, 2016
A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer CellsRajeeva Singh, Yulius Y Setiady, Jose Ponte, et al.
Frontiers in Immunology|March 8, 2024
IL11-mediated stromal cell activation may not be the master regulator of pro-fibrotic signaling downstream of TGFβYunhao Tan, Kenta Mosallanejad, Qingxiu Zhang, et al.
Pageof 3